



CancerCARE

Right Care. Right Time. Right Place.

Pre-treatment Review Program

Take **CONTROL**.

As a plan advisor or health plan, controlling the cancer spend is paramount for plan success. The combination of new treatments, extended remissions, improved diagnostic tools and unrealistic outcome expectations contribute to compounding double digit increases. CancerCARE's Pre-treatment Review (PTR) program is designed to improve outcomes and significantly lower costs.



Pre-treatment Review **Advantages**:



Physicians call CancerCARE directly, not a UR/UM department.

To seriously impact cancer costs, direct communication between CancerCARE and the provider during the care planning process is required. When contacted, CancerCARE's nurses use specialized software that identifies best outcome NCCN Guideline® treatments based on the patient's test results, staging and genetic make-up. Roughly 17% of initial treatment requests are amended based on CancerCARE's treatment recommendation.



Engagement Rises To nearly 100% - For Both Physicians & members.

In the Pretreatment Review Program, nearly 100% of physicians participate because CancerCARE confirms benefit eligibility and authorizes treatments. Armed with disease, staging and treatment knowledge, nearly all members participate when contacted by CancerCARE.



Reduces Other Costs Like Hospitalizations & Expensive Avoidable Care.

As a NCCN Guideline® Licensee, CancerCARE has access to compendia that identify drugs and biologics that reduce hospitalizations due to dehydration and infection risks. CancerCARE always recommends ordering complication management drugs when the treatment guideline is selected.



Engaging At Treatment Planning Enables Centers of Excellent (COE) Quality Second Opinion Diagnostic Reviews To Occur.

With a significant cancer diagnosis, the time between diagnosis and treatment is extremely short. CancerCARE overnights commonly misdiagnosed cancers samples for 24 - 48 hour COE diagnosis and stage confirmation. With a 28% misdiagnosis rate in cancer, this service saves plan resources and lives.



When Managing Cancer, The Plan Is Also Managing Its Transplant Risks!

The most common types of transplants are no longer kidney, liver, or hearts, but rather bone marrow transplants with certain cancer diagnoses. When adding in CancerCARE benefit plan language, plans also add 2.5 pages of transplant language. Early detection and COE involvement leads to better outcomes and lower transplant costs.



Return on Investment for Pre-treatment Review is 16.6/1.

Compared to our Classic - Member Engagement model, the return on investment with our PTR – Physician Engagement model is simply hard to beat. For a very modest PEPM or PMPM charge, nearly all CancerCARE's services are included.

There are many additional reasons why CancerCARE Pre-treatment Review is appropriate for your plan, but there are no other cancer management programs offering such effective tools as CancerCARE. Call for a presentation and to learn more about why CancerCARE is the right solution for your plan.

CancerCARE Pre-treatment Review Program
800-549-9119